**Supplementary Table 1 – Observed to expected and standardized incidence ratios of synchronous and metachronous lung cancers diagnosed after a bladder cancer diagnosis, broken down by discrete time points**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Observed/Expected | SIR (CI) | Excess risk (per 10,000 people) |
| *Synchronous (<6m)* |  |  |  |
| *<1 month* |  |  |  |
| *NMIBC (N= 66071)* | 42/16 | 2.6 (1.9-3.5)\* | 48 |
| *MIBC (N=18879)* | 18/5 | 3.9 (2.3-6.2)\* | 87 |
|  |  |  |  |
| *1-3 months* |  |  |  |
| *NMIBC* | 148/47 | 3.1 (2.7-3.7)\* | 63 |
| *MIBC* | 91/13 | 7.3 (5.9-8.9)\* | 185 |
|  |  |  |  |
| *4-6 months* |  |  |  |
| *NMIBC* | 88/46 | 1.9 (1.5-2.4)\* | 27 |
| *MIBC* | 23/11 | 2.12 (1.3-3.2)\* | 33 |
|  | | | |
| *Metachronous (≥6m)* |  |  |  |
| *7-12 months* |  |  |  |
| *NMIBC (N= 62161)* | 160/90 | 1.8 (1.5-2.1)\* | 23 |
| *MIBC (N=14261)* | 40/18 | 2.2 (1.6-3.0)\* | 36 |
|  |  |  |  |
| *13-59 months* |  |  |  |
| *NMIBC* | 826/410 | 2.0 (1.9-2.2)\* | 30 |
| *MIBC* | 127/57 | 2.24 (1.9-2.7)\* | 36 |
|  |  |  |  |
| *>60 months* |  |  |  |
| *NMIBC* | 80/42 | 1.9 (1.5-2.4)\* | 26 |
| *MIBC* | 10/5 | 2.1 (1.0-3.9)\* | 32 |

O/E: number of observed cases/number of expected cases; SIR: standardized incidence ratio; \*p=<0.05